TRAVATAN e изследван при пациенти с умерени до тежки увреждания на черния дроб и бъбреците (креатининов клирънс под 14 ml/ min).
TRAVATAN has been studied in patients with mild to severe hepatic impairment and in patients with mild to severe renal impairment (creatinine clearance as low as 14 ml/ min).